

Anti-LRRC32/TGFβ1 Antibody (Livmoniplimab)

Introduction

Livmoniplimab (ABBV-151) is an anti-GARP/TGF-β1 monoclonal antibody that blocks the release of active TGF-β1. Livmoniplimab has antitumor activity in mice with colon cancer. Livmoniplimab can be used in the study of locally advanced or metastatic solid tumors.

Product parameters

Alternative Names	ABBV 151, AGRX-115, ABBV151
Target Accession	Q14392
Target	LRRC32 / TGFβ1
CAS number	2412004-88-5
Molecular Weight	146.22 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	-
Isotype	IgG4SP
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 μM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

